Details of the Drug

General Information of Drug (ID: DMQV3IM)

Drug Name
SAR445088
Indication
Disease Entry ICD 11 Status REF
Chronic inflammatory demyelinating polyneuropathy 8C01.3 Phase 2 [1]
Immune thrombocytopenia 3B64 Phase 2 [2]
Autoimmune haemolytic anaemia 3A20 Phase 1 [3]
Cold agglutinin disease 3A20.1 Phase 1 [4]
Cross-matching ID
TTD ID
DHQI14
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C1s component (C1S) TT7LRQH C1S_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic inflammatory demyelinating polyneuropathy
ICD Disease Classification 8C01.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C1s component (C1S) DTT C1S 5.50E-01 1.09 0.91
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04658472) A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04669600) A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP). U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04802057) An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04269551) A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease. U.S.National Institutes of Health.
5 First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.